SlideShare uma empresa Scribd logo
1 de 57
Baixar para ler offline
Hepatitis Virus
Viral Hepatitis - Historical
Perspective
AA““Infectious”Infectious”
““Serum”Serum”
ViralViral
hepatitishepatitis
EntericallyEnterically
transmittedtransmitted
ParenterallyParenterally
transmittedtransmitted
F, G,F, G,
? other? other
EE
NANBNANB
BB DD CC
Viral Hepatitis -
Overview
A B C D E
Source of
virus
feces blood/
blood-derived
body fluids
blood/
blood-derived
body fluids
blood/
blood-derived
body fluids
feces
Route of
transmission
fecal-oral percutaneous
permucosal
percutaneous
permucosal
percutaneous
permucosal
fecal-oral
Chronic
infection
no yes yes yes no
Prevention pre/post-
exposure
immunization
pre/post-
exposure
immunization
blood donor
screening;
risk behavior
modification
pre/post-
exposure
immunization;
risk behavior
modification
ensure safe
drinking
water
Type of Hepatitis
HEPATITIS A VIRUS
HEPATITIS A VIRUS
• RNA Picornavirus
• Single serotype worldwide
• Acute disease and asymptomatic infection
• No chronic infection
• Protective antibodies develop in response to
infection - confers lifelong immunity
HEPATITIS A - CLINICAL
FEATURES
•Jaundice by <6 yrs <10%
age group: 6-14 yrs 40%-50%
>14 yrs 70%-80%
•Rare complications: Fulminant hepatitis
Cholestatic hepatitis
Relapsing hepatitis
•Incubation period: Average 30 days
Range 15-50 days
0 1 2 3 4 5 6 7 8 9 10 11 12 13
Week
Response
Clinical illness
ALT
IgM IgG
HAV in stool
Infection
Viremia
EVENTS IN HEPATITIS A VIRUS INFECTION
CONCENTRATION OF HEPATITIS A VIRUS
IN VARIOUS BODY FLUIDS
Feces
Serum
Saliva
Urine
100 102
104
106
108
1010
BodyFluids
Infectious Doses per mL
• Close personal contact
(e.g., household contact, sex contact,
child day-care centers)
• Contaminated food, water
(e.g., infected food handlers)
• Blood exposure (rare)
(e.g., injection drug use, rarely by
transfusion)
HEPATITIS A VIRUS TRANSMISSION
PREVENTING HEPATITIS A
• Hygiene (e.g., hand washing)
• Sanitation (e.g., clean water sources)
• Hepatitis A vaccine (pre-exposure)
attenuated virus or inactivated virus
• Immune globulin (pre- and post-exposure)
Hepatitis E Virus
•HEV is a 30-32nm non-enveloped particle containing
a s/s (+)sense RNA genome of ~7.5Kb.
•Genetic organization similar (not identical) to
Caliciviruses:
Hepatitis E - Clinical
Features
• Incubation period: Average 40 days
Range 15-60 days
• Case-fatality rate: Overall, 1%-3%
Pregnant women, 5%-
25%
• Illness severity: Increased with age
• Chronic sequelae: None identified
Hepatitis E Virus Infection
Typical Serologic Course
Weeks after
Exposure
Titer
Symptoms
ALT
IgG anti-HEV
IgM anti-HEV
Virus in stool
0 1 2 3 4 5 6 7 8 9 1
0
1
1
1
2
1
3
• Most outbreaks associated with
fecally contaminated drinking water
• Minimal person-to-person
transmission
Hepatitis E -
Epidemiologic Features
• Avoid drinking water (and beverages with
ice) of unknown purity, uncooked shellfish,
and uncooked fruit/vegetables not peeled or
prepared by traveler
• IG prepared from donors in Western
countries does not prevent infection
• Unknown efficacy of IG prepared from
donors in endemic areas
• Vaccine?
Prevention and Control Measures
for Travelers to HEV-Endemic
Regions
HEPATITIS - VIRUS
Hepatitis B - Clinical
Features
• Incubation period: Average 60-90 days
Range 45-180 days
• Clinical illness (jaundice): <5 yrs, <10%
³5 yrs, 30%-50%
• Acute case-fatality rate: 0.5%-1%
• Chronic infection: <5 yrs, 30%-90%
³5 yrs, 2%-10%
carrier state (350m )
• Premature mortality from
chronic liver disease: 15%-25%
Acute Viral Hepatitis Source: CDC
Hepatitis B Virus
• Baruch Blumberg,
1963: ‘Australian
antigen - Au'.
• 1967: Au was a viral
antigen = HBsAg
(surface antigen)
• Dane, 1970:
Discovered 42nm
'Dane particles‘
HBcAg (core antigen).
• 1973: HBeAg
discovered
(endogenous antigen
= a truncated version
of HBcAg).
secreted filament
secreted sphere
hepatitis B virion
HEPATITIS - VIRUS
• spherical,
• enveloped (? lipid-
containing, detergent
disrupted ?)
• 42-47nm diameter
• d/s DNA
• an RNA-dependent DNA
polymerase (i.e. reverse
transcriptase)
• family
Hepadnaviridae
HBV genome organization
two uneven strands
of DNA:
(-)sense strand:
3.0 - 3.3kb
(+)sense strand:
1.7 - 2.8kb
(
(
(
ccc-DNA
RNA
Precore, L, M, S + X
proteins
Capsid
protein
P protein
Reverse transcription
ER/IC
Golgi
The HBV infectious cycle
RNA pregenome
cap
ε
four open reading
frames (ORFs) :
S,C,P,X
• S – HBsAg
• C – HBcAg
C + preC – HBeAg
• P – polymerase
• X – HBxAg (a
transcriptional
transactivator)
HBsAg & anti-HBsHBsAg & anti-HBs
• HBsAg is an envelope protein & an poor
immunogen -------- replicationreplication
• recovery of acute HBV infection is
characterized by HBsAg/anti-HBs
seroconversion
• passively acquired anti-HBs protectsprotects
individuals from infection with HBV
• Anti-HBs is not strictly a ‘neutralizing’
antibody
HBcAg & anti-HBcHBcAg & anti-HBc
• HBcAg is not detectable in the sera of
some patients.
• immunogen
• IgM anti-HBc – virus replication, acute
infection, transient response
• IgG anti-HBc – do not protect
individuals, chronic infections, alst for a
long time
HBeAg & anti-HBeHBeAg & anti-HBe
• HBeAg is produced when virus isHBeAg is produced when virus is
replicating.replicating.
• HBeAg is correlated strongly with theHBeAg is correlated strongly with the
detection of viral DNA, virons and thedetection of viral DNA, virons and the
viral DNA polymerase in the serum.viral DNA polymerase in the serum.
• The disappearace of HBeAg andThe disappearace of HBeAg and
replacement with anti-Hbe indicates thatreplacement with anti-Hbe indicates that
the patient isthe patient is respondingresponding to the infectionto the infection
and will clear HBsAg.and will clear HBsAg.
Acute Hepatitis B Virus Infection with Recovery
Typical Serologic Course
Weeks after
Titer
Symptoms
HBeAg anti-HBe
Total anti-HBc
IgM anti-HBc anti-HBsHBsAg
0 4 8 12 16 20 24 28 32 36 52 100
HEPATITIS - VIRUS
Progression to Chronic Hepatitis B Virus
Infection
Typical Serologic Course
Weeks after Exposure
Titer
IgM anti-HBc
Total anti-
HBc
HBsAg
Acute
(6 months)
HBeAg
Chronic
(Years)
anti-HBe
0 4 8 12 16 20 24 28 32 36 52 Years
SummarySummary
Hepatitis B Lab Tests (1)
• HBV: Hepatitis B virus.
• HBsAg: Hepatitis B surface antigen. Marker of
infectivity when found in serum.
• anti-HBs: Antibody to HBsAg. Marker of immunity
when found in serum.
• HBcAg: Hepatitis B core antigen. No commercial test
available for this.
• anti-HBc: Antibody HBcAg. Marker of past or current
infection.
• IgM anti-HBc: IgM is an antibody subclass of
anti-HBc. Indicates recent infection with HBV
(<4-6 mos.).
• IgG anti-HBc: IgG is a subclass of anti-HBc. Indicates
“older” infection with HBV.
• HBeAg: Hepatitis B “e” antigen. Can only be present if
HBsAg is positive. Marker of high degree of infectivity.
• Anti-HBe: Antibody to “e” antigen. May be present in
infected or immune person.
Hepatitis B Lab Tests (2)
HBsAg negative
antiHBc negative susceptible
antiHBs negative
HBsAg negative
antiHBc positive immune due to natural infection
antiHBs positive
HBsAg positive
antiHBc positive acutely infected
IgM antiHBc positive
antiHBs negative
HBsAg positive
antiHBc positive chronically
IgM antiHBc negative infected
antiHBs negative
Interpretation of Hepatitis B Panel
HBsAg negative
antiHBc positive four possible interpretations
antiHBs negative (see next slide)
HBsAg negative
antiHBc negative immune due to vaccine
antiHBs positive
Four possible interpretations
of isolated antiHBc positive
1. May be recovering from acute HBV infection.
2. May be distantly immune and test not sensitive
enough to detect very low level of anti-HBs in serum.
3. May be susceptible with a false positive anti-HBc.
4. May be undetectable level of HBsAg present in the
serum and the person is actually a carrier.
HEPATITIS - VIRUS
Concentration of Hepatitis B
Virus
in Various Body Fluids
High Moderate
Low/Not
Detectable
blood semen urine
serum vaginal fluid feces
wound exudates saliva sweat
tears
breastmilk
Having sex without condoms with someone who
has hepatitis B
Main Ways to Get Hepatitis B
You can pass hepatitis B to others if you have just
gotten the virus (acute hepatitis) or if you are a
carrier of the virus (chronic hepatitis).
Sharing needles and syringes
Being born to a mother who has hepatitis B
Parenteral
Perinatal
Sexual
• If you have hepatitis B and a tiny bit of your
blood gets inside your baby at birth.
How does a baby get hepatitis B
from mother?
CONTROL
Passive immunization
• Hyperimmune
hepatitis B
immunoglobulin
HBIG
Active immunization
• Vaccine
HBsAg
If you have never had hepatitis B,
you can get 3 shots . . .
. . . and get long lasting protection.
321
Hepatitis B can be prevented!
6 months old
Hepatitis B
Vaccine
Baby Shots
for Hepatitis B
if the mother has Hepatitis B
1 - 2 months old
Hepatitis B
Vaccine
+
Birth
H-BIG
Hepatitis B
Vaccine
Hepatitis D (Delta) Virus
HBsAg
RNA
δ antigen
• Coinfection
–severe acute disease
–low risk of chronic infection
• Superinfection
–usually develop chronic HDV
infection
–high risk of severe chronic liver
disease
Hepatitis D - Clinical
Features
• Percutanous
exposures
–injecting drug use
• Permucosal exposures
–sex contact
Hepatitis D Virus
Modes of Transmission
• HBV-HDV Coinfection
Pre or postexposure prophylaxis to
prevent HBV infection
• HBV-HDV Superinfection
Education to reduce risk behaviors
among persons with chronic HBV
infection
Hepatitis D -
Prevention
HEPATITIS - VIRUS
Hepatitis CHepatitis C
Flaviviridae
a positive-sense RNA molecule 9.5kb in length
Features of Hepatitis C VirusFeatures of Hepatitis C Virus
InfectionInfection
Incubation periodIncubation period Average 6-7 weeksAverage 6-7 weeks
Range 2-26 weeksRange 2-26 weeks
Acute illness (jaundice)Acute illness (jaundice) Mild (Mild (<<20%)20%)
Case fatality rateCase fatality rate LowLow
Chronic infectionChronic infection 60%-85%60%-85%
Chronic hepatitisChronic hepatitis 10%-70%10%-70%
CirrhosisCirrhosis <5%-20%<5%-20%
Mortality from CLDMortality from CLD 1%-5%1%-5%
Age-
related
Serologic Pattern of Acute HCV Infection
with Recovery
Symptoms +/-
Time after
Exposure
Titer anti-
HCV
ALT
Normal
0 1 2 3 4 5 6 1 2 3 4
YearsMonths
HCV RNA
Serologic Pattern of Acute HCV Infection with
Progression to Chronic Infection
Symptoms +/-
Time after
Exposure
Titer anti-
HCV
ALT
Normal
0 1 2 3 4 5 6 1 2 3 4
YearsMonths
HCV RNA
Reduce or Eliminate Risks for
Acquiring HCV Infection
• Screen and test donors
• Virus inactivation of plasma-derived products
• Risk-reduction counseling and services
– Obtain history of high-risk drug and sex behaviors
– Provide information on minimizing risky behavior,
including referral to other services
– Vaccinate against hepatitis A and/or hepatitis B
• Safe injection and infection control practices
HCV Prevention and Control
Preventing HCV Transmission to
Others
• Do not donate blood, body organs, other
tissue or semen
• Do not share items that might have blood on
them
– personal care (e.g., razor, toothbrush)
– home therapy (e.g., needles)
• Cover cuts and sores on the skin
Avoid Direct Exposure to Blood
Other Transmission Issues
• HCV not spread by kissing, hugging,
sneezing, coughing, food or water, sharing
eating utensils or drinking glasses, or casual
contact
• Do not exclude from work, school, play,
child-care or other settings based on HCV
infection status
HCV Counseling

Mais conteúdo relacionado

Mais procurados (20)

Hepatitis c
Hepatitis cHepatitis c
Hepatitis c
 
Hepatitis B
Hepatitis BHepatitis B
Hepatitis B
 
Hepatitis b
Hepatitis bHepatitis b
Hepatitis b
 
Acinetobacter baumannii an update
Acinetobacter baumannii an update Acinetobacter baumannii an update
Acinetobacter baumannii an update
 
Viral hepatitis b
Viral hepatitis bViral hepatitis b
Viral hepatitis b
 
Hepatitis B Virus (hbv)
Hepatitis B Virus (hbv)Hepatitis B Virus (hbv)
Hepatitis B Virus (hbv)
 
Hepatitis B
Hepatitis BHepatitis B
Hepatitis B
 
Hiv
HivHiv
Hiv
 
Hepatitis B virus
Hepatitis B virusHepatitis B virus
Hepatitis B virus
 
COVID 19- Diagnosis and Treatment
COVID 19- Diagnosis and TreatmentCOVID 19- Diagnosis and Treatment
COVID 19- Diagnosis and Treatment
 
Hepatitis B, Viral Hepatitis
Hepatitis B, Viral HepatitisHepatitis B, Viral Hepatitis
Hepatitis B, Viral Hepatitis
 
Hepatitis B virus
Hepatitis B  virusHepatitis B  virus
Hepatitis B virus
 
35. hepatitis
35. hepatitis35. hepatitis
35. hepatitis
 
Hepatitis B Virus
Hepatitis B VirusHepatitis B Virus
Hepatitis B Virus
 
Hepatitis Viral Markers
Hepatitis Viral MarkersHepatitis Viral Markers
Hepatitis Viral Markers
 
Viral vaccines
Viral vaccinesViral vaccines
Viral vaccines
 
Covid 19 Vaccines
Covid 19 VaccinesCovid 19 Vaccines
Covid 19 Vaccines
 
HEPATITIS C
HEPATITIS CHEPATITIS C
HEPATITIS C
 
HIV (human immunodeficiency virus)
HIV (human immunodeficiency virus) HIV (human immunodeficiency virus)
HIV (human immunodeficiency virus)
 
laboratory diagnosis of viral hepatitis (B & C)
laboratory diagnosis of viral hepatitis (B & C)laboratory diagnosis of viral hepatitis (B & C)
laboratory diagnosis of viral hepatitis (B & C)
 

Semelhante a HEPATITIS - VIRUS

Hepatitis a, e, b
Hepatitis a, e, bHepatitis a, e, b
Hepatitis a, e, bBAU
 
hepatitis B & D.pptx
hepatitis B & D.pptxhepatitis B & D.pptx
hepatitis B & D.pptxMeenachi Ct
 
immunodiagnosis of viral hepatitis students (1).ppt
immunodiagnosis of viral hepatitis students (1).pptimmunodiagnosis of viral hepatitis students (1).ppt
immunodiagnosis of viral hepatitis students (1).pptMUHAMMADCHAUDHRY39
 
Hepatitispptfinal anoop k r
Hepatitispptfinal anoop k rHepatitispptfinal anoop k r
Hepatitispptfinal anoop k ranoop k r
 
AU AVH lecture note.pptx
AU AVH lecture note.pptxAU AVH lecture note.pptx
AU AVH lecture note.pptxNatanA7
 
Hepatitis b virus (hbv) infection a silent epidemic
Hepatitis b virus (hbv) infection a silent epidemicHepatitis b virus (hbv) infection a silent epidemic
Hepatitis b virus (hbv) infection a silent epidemicAung Zayar Paing
 
Hepatitis B and C viruses
Hepatitis B and C virusesHepatitis B and C viruses
Hepatitis B and C virusesDrm Aliraqi
 
Hepatitis B In children by Dr. kaniz fathema, resident, paediatric Gastroente...
Hepatitis B In children by Dr. kaniz fathema, resident, paediatric Gastroente...Hepatitis B In children by Dr. kaniz fathema, resident, paediatric Gastroente...
Hepatitis B In children by Dr. kaniz fathema, resident, paediatric Gastroente...kaniz fathema
 
35-hepatitis-110919093359-phpapp01.pptx
35-hepatitis-110919093359-phpapp01.pptx35-hepatitis-110919093359-phpapp01.pptx
35-hepatitis-110919093359-phpapp01.pptxMonish Pokra
 

Semelhante a HEPATITIS - VIRUS (20)

Hepat seminar
Hepat seminarHepat seminar
Hepat seminar
 
Hepatitis a, e, b
Hepatitis a, e, bHepatitis a, e, b
Hepatitis a, e, b
 
Hepatitis ppt
Hepatitis pptHepatitis ppt
Hepatitis ppt
 
Acute liver disease
Acute liver diseaseAcute liver disease
Acute liver disease
 
hepatitis B & D.pptx
hepatitis B & D.pptxhepatitis B & D.pptx
hepatitis B & D.pptx
 
immunodiagnosis of viral hepatitis students (1).ppt
immunodiagnosis of viral hepatitis students (1).pptimmunodiagnosis of viral hepatitis students (1).ppt
immunodiagnosis of viral hepatitis students (1).ppt
 
Hepatitispptfinal anoop k r
Hepatitispptfinal anoop k rHepatitispptfinal anoop k r
Hepatitispptfinal anoop k r
 
Dr kgm hep b
Dr kgm  hep bDr kgm  hep b
Dr kgm hep b
 
Hepatitis b,c, &d
Hepatitis b,c, &dHepatitis b,c, &d
Hepatitis b,c, &d
 
AU AVH lecture note.pptx
AU AVH lecture note.pptxAU AVH lecture note.pptx
AU AVH lecture note.pptx
 
Hepatitis b virus (hbv) infection a silent epidemic
Hepatitis b virus (hbv) infection a silent epidemicHepatitis b virus (hbv) infection a silent epidemic
Hepatitis b virus (hbv) infection a silent epidemic
 
Swtz seminar
Swtz seminarSwtz seminar
Swtz seminar
 
Hepatitis A-E
Hepatitis A-EHepatitis A-E
Hepatitis A-E
 
Viral hepatitis 6
Viral hepatitis 6Viral hepatitis 6
Viral hepatitis 6
 
Hepatitis B and C viruses
Hepatitis B and C virusesHepatitis B and C viruses
Hepatitis B and C viruses
 
Hepatitis B In children by Dr. kaniz fathema, resident, paediatric Gastroente...
Hepatitis B In children by Dr. kaniz fathema, resident, paediatric Gastroente...Hepatitis B In children by Dr. kaniz fathema, resident, paediatric Gastroente...
Hepatitis B In children by Dr. kaniz fathema, resident, paediatric Gastroente...
 
Hepatitis
HepatitisHepatitis
Hepatitis
 
hepatitis b and d
hepatitis b and dhepatitis b and d
hepatitis b and d
 
Viral hepatitis
Viral hepatitisViral hepatitis
Viral hepatitis
 
35-hepatitis-110919093359-phpapp01.pptx
35-hepatitis-110919093359-phpapp01.pptx35-hepatitis-110919093359-phpapp01.pptx
35-hepatitis-110919093359-phpapp01.pptx
 

Último

SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 

Último (20)

SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 

HEPATITIS - VIRUS

  • 2. Viral Hepatitis - Historical Perspective AA““Infectious”Infectious” ““Serum”Serum” ViralViral hepatitishepatitis EntericallyEnterically transmittedtransmitted ParenterallyParenterally transmittedtransmitted F, G,F, G, ? other? other EE NANBNANB BB DD CC
  • 3. Viral Hepatitis - Overview A B C D E Source of virus feces blood/ blood-derived body fluids blood/ blood-derived body fluids blood/ blood-derived body fluids feces Route of transmission fecal-oral percutaneous permucosal percutaneous permucosal percutaneous permucosal fecal-oral Chronic infection no yes yes yes no Prevention pre/post- exposure immunization pre/post- exposure immunization blood donor screening; risk behavior modification pre/post- exposure immunization; risk behavior modification ensure safe drinking water Type of Hepatitis
  • 5. HEPATITIS A VIRUS • RNA Picornavirus • Single serotype worldwide • Acute disease and asymptomatic infection • No chronic infection • Protective antibodies develop in response to infection - confers lifelong immunity
  • 6. HEPATITIS A - CLINICAL FEATURES •Jaundice by <6 yrs <10% age group: 6-14 yrs 40%-50% >14 yrs 70%-80% •Rare complications: Fulminant hepatitis Cholestatic hepatitis Relapsing hepatitis •Incubation period: Average 30 days Range 15-50 days
  • 7. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 Week Response Clinical illness ALT IgM IgG HAV in stool Infection Viremia EVENTS IN HEPATITIS A VIRUS INFECTION
  • 8. CONCENTRATION OF HEPATITIS A VIRUS IN VARIOUS BODY FLUIDS Feces Serum Saliva Urine 100 102 104 106 108 1010 BodyFluids Infectious Doses per mL
  • 9. • Close personal contact (e.g., household contact, sex contact, child day-care centers) • Contaminated food, water (e.g., infected food handlers) • Blood exposure (rare) (e.g., injection drug use, rarely by transfusion) HEPATITIS A VIRUS TRANSMISSION
  • 10. PREVENTING HEPATITIS A • Hygiene (e.g., hand washing) • Sanitation (e.g., clean water sources) • Hepatitis A vaccine (pre-exposure) attenuated virus or inactivated virus • Immune globulin (pre- and post-exposure)
  • 12. •HEV is a 30-32nm non-enveloped particle containing a s/s (+)sense RNA genome of ~7.5Kb. •Genetic organization similar (not identical) to Caliciviruses:
  • 13. Hepatitis E - Clinical Features • Incubation period: Average 40 days Range 15-60 days • Case-fatality rate: Overall, 1%-3% Pregnant women, 5%- 25% • Illness severity: Increased with age • Chronic sequelae: None identified
  • 14. Hepatitis E Virus Infection Typical Serologic Course Weeks after Exposure Titer Symptoms ALT IgG anti-HEV IgM anti-HEV Virus in stool 0 1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3
  • 15. • Most outbreaks associated with fecally contaminated drinking water • Minimal person-to-person transmission Hepatitis E - Epidemiologic Features
  • 16. • Avoid drinking water (and beverages with ice) of unknown purity, uncooked shellfish, and uncooked fruit/vegetables not peeled or prepared by traveler • IG prepared from donors in Western countries does not prevent infection • Unknown efficacy of IG prepared from donors in endemic areas • Vaccine? Prevention and Control Measures for Travelers to HEV-Endemic Regions
  • 18. Hepatitis B - Clinical Features • Incubation period: Average 60-90 days Range 45-180 days • Clinical illness (jaundice): <5 yrs, <10% ³5 yrs, 30%-50% • Acute case-fatality rate: 0.5%-1% • Chronic infection: <5 yrs, 30%-90% ³5 yrs, 2%-10% carrier state (350m ) • Premature mortality from chronic liver disease: 15%-25%
  • 19. Acute Viral Hepatitis Source: CDC
  • 21. • Baruch Blumberg, 1963: ‘Australian antigen - Au'. • 1967: Au was a viral antigen = HBsAg (surface antigen) • Dane, 1970: Discovered 42nm 'Dane particles‘ HBcAg (core antigen). • 1973: HBeAg discovered (endogenous antigen = a truncated version of HBcAg). secreted filament secreted sphere hepatitis B virion
  • 23. • spherical, • enveloped (? lipid- containing, detergent disrupted ?) • 42-47nm diameter • d/s DNA • an RNA-dependent DNA polymerase (i.e. reverse transcriptase) • family Hepadnaviridae
  • 24. HBV genome organization two uneven strands of DNA: (-)sense strand: 3.0 - 3.3kb (+)sense strand: 1.7 - 2.8kb
  • 25. ( ( ( ccc-DNA RNA Precore, L, M, S + X proteins Capsid protein P protein Reverse transcription ER/IC Golgi The HBV infectious cycle RNA pregenome cap ε
  • 26. four open reading frames (ORFs) : S,C,P,X • S – HBsAg • C – HBcAg C + preC – HBeAg • P – polymerase • X – HBxAg (a transcriptional transactivator)
  • 27. HBsAg & anti-HBsHBsAg & anti-HBs • HBsAg is an envelope protein & an poor immunogen -------- replicationreplication • recovery of acute HBV infection is characterized by HBsAg/anti-HBs seroconversion • passively acquired anti-HBs protectsprotects individuals from infection with HBV • Anti-HBs is not strictly a ‘neutralizing’ antibody
  • 28. HBcAg & anti-HBcHBcAg & anti-HBc • HBcAg is not detectable in the sera of some patients. • immunogen • IgM anti-HBc – virus replication, acute infection, transient response • IgG anti-HBc – do not protect individuals, chronic infections, alst for a long time
  • 29. HBeAg & anti-HBeHBeAg & anti-HBe • HBeAg is produced when virus isHBeAg is produced when virus is replicating.replicating. • HBeAg is correlated strongly with theHBeAg is correlated strongly with the detection of viral DNA, virons and thedetection of viral DNA, virons and the viral DNA polymerase in the serum.viral DNA polymerase in the serum. • The disappearace of HBeAg andThe disappearace of HBeAg and replacement with anti-Hbe indicates thatreplacement with anti-Hbe indicates that the patient isthe patient is respondingresponding to the infectionto the infection and will clear HBsAg.and will clear HBsAg.
  • 30. Acute Hepatitis B Virus Infection with Recovery Typical Serologic Course Weeks after Titer Symptoms HBeAg anti-HBe Total anti-HBc IgM anti-HBc anti-HBsHBsAg 0 4 8 12 16 20 24 28 32 36 52 100
  • 32. Progression to Chronic Hepatitis B Virus Infection Typical Serologic Course Weeks after Exposure Titer IgM anti-HBc Total anti- HBc HBsAg Acute (6 months) HBeAg Chronic (Years) anti-HBe 0 4 8 12 16 20 24 28 32 36 52 Years
  • 34. Hepatitis B Lab Tests (1) • HBV: Hepatitis B virus. • HBsAg: Hepatitis B surface antigen. Marker of infectivity when found in serum. • anti-HBs: Antibody to HBsAg. Marker of immunity when found in serum. • HBcAg: Hepatitis B core antigen. No commercial test available for this. • anti-HBc: Antibody HBcAg. Marker of past or current infection.
  • 35. • IgM anti-HBc: IgM is an antibody subclass of anti-HBc. Indicates recent infection with HBV (<4-6 mos.). • IgG anti-HBc: IgG is a subclass of anti-HBc. Indicates “older” infection with HBV. • HBeAg: Hepatitis B “e” antigen. Can only be present if HBsAg is positive. Marker of high degree of infectivity. • Anti-HBe: Antibody to “e” antigen. May be present in infected or immune person. Hepatitis B Lab Tests (2)
  • 36. HBsAg negative antiHBc negative susceptible antiHBs negative HBsAg negative antiHBc positive immune due to natural infection antiHBs positive HBsAg positive antiHBc positive acutely infected IgM antiHBc positive antiHBs negative HBsAg positive antiHBc positive chronically IgM antiHBc negative infected antiHBs negative Interpretation of Hepatitis B Panel HBsAg negative antiHBc positive four possible interpretations antiHBs negative (see next slide) HBsAg negative antiHBc negative immune due to vaccine antiHBs positive
  • 37. Four possible interpretations of isolated antiHBc positive 1. May be recovering from acute HBV infection. 2. May be distantly immune and test not sensitive enough to detect very low level of anti-HBs in serum. 3. May be susceptible with a false positive anti-HBc. 4. May be undetectable level of HBsAg present in the serum and the person is actually a carrier.
  • 39. Concentration of Hepatitis B Virus in Various Body Fluids High Moderate Low/Not Detectable blood semen urine serum vaginal fluid feces wound exudates saliva sweat tears breastmilk
  • 40. Having sex without condoms with someone who has hepatitis B Main Ways to Get Hepatitis B You can pass hepatitis B to others if you have just gotten the virus (acute hepatitis) or if you are a carrier of the virus (chronic hepatitis). Sharing needles and syringes Being born to a mother who has hepatitis B Parenteral Perinatal Sexual
  • 41. • If you have hepatitis B and a tiny bit of your blood gets inside your baby at birth. How does a baby get hepatitis B from mother?
  • 42. CONTROL Passive immunization • Hyperimmune hepatitis B immunoglobulin HBIG Active immunization • Vaccine HBsAg
  • 43. If you have never had hepatitis B, you can get 3 shots . . . . . . and get long lasting protection. 321 Hepatitis B can be prevented!
  • 44. 6 months old Hepatitis B Vaccine Baby Shots for Hepatitis B if the mother has Hepatitis B 1 - 2 months old Hepatitis B Vaccine + Birth H-BIG Hepatitis B Vaccine
  • 45. Hepatitis D (Delta) Virus HBsAg RNA δ antigen
  • 46. • Coinfection –severe acute disease –low risk of chronic infection • Superinfection –usually develop chronic HDV infection –high risk of severe chronic liver disease Hepatitis D - Clinical Features
  • 47. • Percutanous exposures –injecting drug use • Permucosal exposures –sex contact Hepatitis D Virus Modes of Transmission
  • 48. • HBV-HDV Coinfection Pre or postexposure prophylaxis to prevent HBV infection • HBV-HDV Superinfection Education to reduce risk behaviors among persons with chronic HBV infection Hepatitis D - Prevention
  • 51. a positive-sense RNA molecule 9.5kb in length
  • 52. Features of Hepatitis C VirusFeatures of Hepatitis C Virus InfectionInfection Incubation periodIncubation period Average 6-7 weeksAverage 6-7 weeks Range 2-26 weeksRange 2-26 weeks Acute illness (jaundice)Acute illness (jaundice) Mild (Mild (<<20%)20%) Case fatality rateCase fatality rate LowLow Chronic infectionChronic infection 60%-85%60%-85% Chronic hepatitisChronic hepatitis 10%-70%10%-70% CirrhosisCirrhosis <5%-20%<5%-20% Mortality from CLDMortality from CLD 1%-5%1%-5% Age- related
  • 53. Serologic Pattern of Acute HCV Infection with Recovery Symptoms +/- Time after Exposure Titer anti- HCV ALT Normal 0 1 2 3 4 5 6 1 2 3 4 YearsMonths HCV RNA
  • 54. Serologic Pattern of Acute HCV Infection with Progression to Chronic Infection Symptoms +/- Time after Exposure Titer anti- HCV ALT Normal 0 1 2 3 4 5 6 1 2 3 4 YearsMonths HCV RNA
  • 55. Reduce or Eliminate Risks for Acquiring HCV Infection • Screen and test donors • Virus inactivation of plasma-derived products • Risk-reduction counseling and services – Obtain history of high-risk drug and sex behaviors – Provide information on minimizing risky behavior, including referral to other services – Vaccinate against hepatitis A and/or hepatitis B • Safe injection and infection control practices HCV Prevention and Control
  • 56. Preventing HCV Transmission to Others • Do not donate blood, body organs, other tissue or semen • Do not share items that might have blood on them – personal care (e.g., razor, toothbrush) – home therapy (e.g., needles) • Cover cuts and sores on the skin Avoid Direct Exposure to Blood
  • 57. Other Transmission Issues • HCV not spread by kissing, hugging, sneezing, coughing, food or water, sharing eating utensils or drinking glasses, or casual contact • Do not exclude from work, school, play, child-care or other settings based on HCV infection status HCV Counseling

Notas do Editor

  1. Before the discovery of hepatitis A virus (HAV) and hepatitis B virus (HBV) during the 1960s and 1970s, patients with viral hepatitis were classified based on epidemiological studies as having either infectious (transmitted person to person by the fecal-oral route) or serum (transmitted by transfusion of blood products) hepatitis. When diagnostic tests for HAV and HBV infections were developed, HAV was found to be the major cause of infectious hepatitis and HBV was found to be the major cause of serum hepatitis. Hepatitis delta virus (HDV), discovered in 1977, is a defective virus requiring the presence of HBV in order to replicate. However, some patients with typical signs and symptoms of viral hepatitis did not have serologic markers of HAV, HBV, or HDV infection and were categorized based on epidemiological characteristics as having either parenterally transmitted non-A, non-B (NANB) hepatitis or enterically transmitted NANB hepatitis. Subsequently, two additional viruses were discovered: hepatitis C virus (HCV) and hepatitis E virus (HEV). HCV is the major cause of parenterally transmitted NANB and HEV is the major cause of enterically transmitted NANB hepatitis. In addition, some patients with typical signs and symptoms of acute viral hepatitis do not have serologic markers of any of these types of viral hepatitis and can be classified as having non-ABCDE hepatitis. New viruses might be discovered in patients with non-ABCDE hepatitis.
  2. This is an electron micrograph of HAV that causes hepatitis A. See the next slide for specifics about this virus.
  3. Hepatitis A is caused by HAV, a 27-nm ribonucleic acid (RNA) agent that is classified as a picornavirus. Only one serotype has been observed among HAV isolates collected from various parts of the world. HAV causes both acute disease and asymptomatic infection. HAV does not cause chronic infection. Total antibody to HAV develops in response to infection and confers lifelong immunity from future HAV infection.
  4. The average incubation period for hepatitis A is 30 days, with a range of 15 to 50 days. Patients characteristically have abrupt onset of symptoms which can include fever, malaise, anorexia, nausea, abdominal discomfort, dark urine, and jaundice. The severity of clinical disease associated with HAV infection increases with increasing age; jaundice occurs among less than 10% of children younger than 6 years of age, 40%-50% of older children, and 70%-80% of adults. Complications of hepatitis A include fulminant hepatitis, in which the case fatality rate can be greater than 50% despite medical interventions such as liver transplantation; cholestatic hepatitis, with very high bilirubin levels that can persist for months; and relapsing hepatitis, in which exacerbations can occur weeks to months after apparent recovery. Chronic infection does not occur following HAV infection.
  5. The diagnosis of acute HAV infection is confirmed during the acute or early convalescent phase of infection by the presence of IgM antibodies to HAV (IgM anti-HAV). IgM anti-HAV is generally present 5-10 days before the onset of symptoms and is no longer detectable in the vast majority of patients 6 months later. IgG anti-HAV, which also appears early in the course of infection, remains detectable for the lifetime of the individual and confers lifelong protection against infection. Commercial tests are available for the detection of IgM and total (IgM and IgG) anti-HAV in serum. In infected persons, HAV replicates in the liver, is excreted in bile, and is shed in the stool. Peak infectivity occurs during the 2-week period before onset of jaundice or elevation of liver enzymes, when the concentration of virus in stool is highest. The concentration of virus in stool declines after jaundice appears. Children and infants can shed HAV for longer periods than adults, up to several months after the onset of clinical illness. Chronic shedding of HAV in feces does not occur; however, shedding can occur in persons who have relapsing illness. Viremia occurs soon after infection and persists through the period of liver enzyme (alanine aminotransferase [ALT]) elevation. HAV RNA can be detected in the blood and stool of most persons during the acute phase of infection by using nucleic acid amplification methods, such as PCR, and nucleic acid sequencing has been used to determine the relatedness of HAV isolates. These methods, however, are available in only a limited number of research laboratories and are not used generally for diagnostic purposes.
  6. Feces can contain up to 108 infectious virions per milliliter and are the primary source of HAV. Viremia occurs during the preclinical and clinical phases of illness, and HAV has been transmitted by transfusion (before screening of blood and blood products for HAV was initiated) and by injection drug use. Virus has also been found in saliva and urine during the incubation period in experimentally infected animals, but transmission by saliva or urine has not been reported to occur.
  7. Transmission of HAV generally occurs when susceptible persons put anything in their mouths that has been contaminated with the feces of an infected person. Close personal contact is the most common mode of HAV transmission, as demonstrated by infections among household and sex contacts of persons with hepatitis A and among children in day-care center outbreaks. Contaminated food and water can also serve as vehicles of HAV transmission. HAV transmission can occur when an infected food handler directly handles uncooked or cooked foods. Outbreaks have also been reported in association with foods contaminated before wholesale distribution, such as fresh vegetables contaminated at the time of harvesting or processing. HAV transmission can occur as a result of blood exposures such as injecting drug use or blood transfusion because viremia can occur prior to the onset of illness in infected persons. Screening of blood products for HAV has essentially eliminated the already extremely low risk associated with transfusion.
  8. Good hygienic practices and adequate sanitation are important elements in the prevention of HAV infection, particularly in the developing world. However, hepatitis A vaccine is the key component in the overall strategy to prevent HAV infection in the United States. Immune globulin is also available for pre-exposure and post-exposure prophylaxis.